Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thrombosis Events May Be Clarified By e-CYPHER Data Expected In February

This article was originally published in The Gray Sheet

Executive Summary

FDA's public health notification related to adverse events for J&J/Cordis' Cypher is intended to generate further data collection for the drug-eluting stent rather than raise undue concern over clotting issues, the agency says

You may also be interested in...



Two-Year TAXUS-IV Stent Data Show Slight Increase In Thrombosis

Boston Scientific's Taxus drug-eluting stent is associated with slightly greater long-term thrombosis than the bare-metal Express in the TAXUS-IV study

Two-Year TAXUS-IV Stent Data Show Slight Increase In Thrombosis

Boston Scientific's Taxus drug-eluting stent is associated with slightly greater long-term thrombosis than the bare-metal Express in the TAXUS-IV study

Cypher Warning Letter Cites Systemic GMP Problems At Multiple Facilities

Johnson & Johnson/Cordis' inability to provide timely failure analysis reports of Cypher-related thrombosis complaints is one of several GMP violations cited in an April 1 FDA 1warning letter

Related Content

UsernamePublicRestriction

Register

MT019272

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel